Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor – Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models

      Background: Inadequate delivery of T cells into the tumour milieu, as well as a lack of specificity and persistence of their action hinders the potential of adoptive T cell therapy (ACT). To overcome these issues, we propose to arm T cells with synthetic agonistic receptors (SARs) that are conditionally activated only in the presence of a target tumour associated antigen, and a cross-linking bispecific antibody (BiAb) specific for both T cell and tumour cell.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect